Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Anti-Angiogenic Cancer Research

Executive Summary: Anlotinib hydrochloride is a novel, small-molecule multi-target tyrosine kinase inhibitor (TKI) that selectively inhibits VEGFR2, PDGFRβ, and FGFR1, all key mediators in angiogenesis (Xie et al., 2018). The compound exhibits nanomolar inhibitory potency in endothelial cell migration and capillary tube formation assays, with minimal cytotoxicity up to 1 μM (Xie et al., 2018). Oral bioavailability ranges from 28–77% in rodents and dogs, and plasma protein binding is high (93–97%) (APExBIO). Anlotinib outperforms sunitinib and sorafenib in comparative preclinical tumor models (Xie et al., 2018). Safety studies indicate a high LD₅₀ (1735.9 mg/kg, 14 days oral) and low off-target toxicity (APExBIO).

Biological Rationale

Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is essential for tumor growth and metastasis. Tumor progression beyond 1 mm³ requires neovascularization to supply oxygen and nutrients (Xie et al., 2018). The vascular endothelial growth factor (VEGF) family and its receptors (VEGFR1, VEGFR2, VEGFR3) are critical regulators of this process. VEGFR2, in particular, is central to endothelial cell migration, proliferation, and tube formation. Platelet-derived growth factor receptor β (PDGFRβ) and fibroblast growth factor receptor 1 (FGFR1) also contribute to angiogenic signaling. Inhibition of these pathways is a validated strategy in cancer therapeutics. Targeting multiple angiogenic RTKs can simultaneously block redundant and compensatory pathways, enhancing anti-tumor efficacy (Related Article—this article updates pharmacokinetic and safety details).

Mechanism of Action of Anlotinib hydrochloride

Anlotinib hydrochloride acts as an ATP-competitive inhibitor of multiple receptor tyrosine kinases. It exhibits high selectivity for VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (8.7 ± 3.4 nM), and FGFR1 (11.7 ± 4.1 nM) in biochemical kinase assays at 25°C, pH 7.4 (Xie et al., 2018). These values surpass the potency of sunitinib, sorafenib, and nintedanib. Anlotinib blocks ligand-induced phosphorylation of target RTKs, thereby suppressing downstream ERK signaling. In human vascular endothelial cells (EA.hy 926), anlotinib inhibits VEGF/PDGF-BB/FGF-2-induced cell migration and tube formation in a concentration-dependent manner. At ≤1 μM, it does not induce cytotoxicity, enabling its use in functional assays. In vivo, anlotinib causes a reduction in tumor vascular density and inhibits tumor growth in murine xenograft models. The compound’s action is not limited to VEGFR2; it also reduces cross-talk via PDGFRβ and FGFR1, blocking compensatory angiogenic mechanisms (Related Article—this piece clarifies the multi-pathway selectivity and functional benchmark data).

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 kinase activity with IC₅₀ < 6 nM, outperforming sunitinib and sorafenib in the same assay conditions (Xie et al., 2018, Table 1).
• In EA.hy 926 endothelial cell migration assays, anlotinib suppresses VEGF-induced migration at sub-10 nM concentrations without cytotoxicity (Xie et al., 2018, Figure 2).
• Capillary-like tube formation is inhibited by anlotinib in a dose-dependent manner (IC₅₀ < 12 nM); tested at 37°C, 5% CO₂, 48 h incubation (Xie et al., 2018, Figure 3).
• Oral bioavailability in rats: 28–58%; in dogs: 41–77%; plasma protein binding: 93–97% (in vitro, human plasma, equilibrium dialysis) (APExBIO).
• Terminal half-life: 5.1 ± 1.6 h in rats; 22.8 ± 11.0 h in dogs; metabolism mainly via CYP3A4 (Xie et al., 2018).
• No significant cytotoxicity up to 1 μM in EA.hy 926 cells; LD₅₀: 1735.9 mg/kg (14-day oral, rat) (APExBIO).
• Outperforms sunitinib in in vivo tumor regression studies in nude mice (daily oral dosing, 10 mg/kg, 21 days) (Xie et al., 2018, Figure 5).

For a broader discussion on molecular mechanisms and translational research, see this article—here, we emphasize updated pharmacokinetics and validated cell-based benchmarks.

Applications, Limits & Misconceptions

Applications: Anlotinib hydrochloride is used in cancer biology to dissect angiogenesis mechanisms, screen anti-angiogenic compounds, and model tumor progression. Its low cytotoxicity and high selectivity make it ideal for endothelial cell migration and capillary tube formation assays. It is also used in pharmacokinetics and drug metabolism research, including CYP3A-mediated pathways. The compound supports preclinical studies in hepatocellular carcinoma, glioblastoma, and other solid tumors (Related Article—this piece is extended here with new bioavailability and metabolism data).

Common Pitfalls or Misconceptions

• Anlotinib is not cytotoxic to most non-endothelial cell types below 1 μM; direct anti-proliferative effects on tumor cells require higher concentrations or prolonged exposure (Xie et al., 2018).
• Inhibition of angiogenesis does not necessarily equate to tumor regression in all models; compensatory pathways may emerge.
• The compound is not approved for clinical use outside research settings; supplied by APExBIO for research use only (APExBIO).
• Pharmacokinetic values (e.g., bioavailability, half-life) may not extrapolate directly from animals to humans due to interspecies differences.
• Despite low risk, in vitro CYP3A4 inhibition could potentially affect metabolism of co-administered compounds at supratherapeutic concentrations.

Workflow Integration & Parameters

Anlotinib hydrochloride is supplied as a hydrochloride salt for high solubility and stability. Store at -20°C, protected from light and moisture. Typical working concentrations in endothelial assays: 1–100 nM for migration or tube formation assays; up to 1 μM for non-cytotoxic controls. For in vivo studies, oral dosing in rodents ranges from 1–20 mg/kg/day. Metabolism studies should account for CYP3A-mediated biotransformation. Anlotinib is compatible with most standard cell culture media and vehicle systems (e.g., DMSO ≤0.1%). Refer to the Anlotinib hydrochloride product page for preparation and safety data. For workflow troubleshooting and protocol optimization, see this resource—the present article updates with new LD₅₀ and target selectivity data.

Conclusion & Outlook

Anlotinib hydrochloride, as supplied by APExBIO, is a validated multi-target tyrosine kinase inhibitor for anti-angiogenic research. Its superior potency against VEGFR2, PDGFRβ, and FGFR1, combined with favorable PK and safety profiles, positions it as a benchmark tool for preclinical cancer and endothelial biology studies. Ongoing research explores its translational potential in combination therapies and resistant tumor models. For researchers requiring a potent, well-characterized angiogenesis inhibitor, Anlotinib hydrochloride (C8688) is a robust choice supported by extensive peer-reviewed and manufacturer data (Xie et al., 2018; APExBIO).